Ariclaim (duloxetine)
- Region
- 🇪🇺 EU
- Active substance
- duloxetine
- Company
- Eli Lilly Nederland B.V.
- Status
- Withdrawn
- Therapeutic area
- Diabetic Neuropathies
- EU approval
- Wed 11 Aug 2004
- Application
- EMEA/H/C/000552
- ATC
- N06AX21
- Official record
- www.ema.europa.eu
Indication
Treatment of diabetic peripheral neuropathic pain. Ariclaim is indicated in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Duloxetine Viatris (previously Duloxetine Mylan) Authorised · Viatris Limited
- 🇺🇸 Duloxetine Hydrochloride Approved · Almatica
- 🇪🇺 Duloxetine Zentiva Authorised · Zentiva k.s.
- 🇪🇺 Duloxetine Lilly Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Cymbalta Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Yentreve Authorised · Eli Lilly Nederland B.V.
- 🇪🇺 Nodetrip (previously Xeristar) Withdrawn · Esteve Pharmaceuticals, S.A.
- 🇪🇺 Duloxetine Sandoz Application withdrawn · Sandoz GmbH
- 🇪🇺 Duloxetine Boehringer Ingelheim Withdrawn · Boehringer Ingelheim International GmbH
Follow Ariclaim
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.